Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation

被引：0

作者：

Imanishi, Yoshinori ^{[1
]}

Matsui, Kumi ^{[1
]}

Ishida, Kenichiro ^{[2
]}

Ito, Shin-ichi ^{[2
]}

Matsuura, Katsuhiko ^{[1
]}

Deguchi, Takashi ^{[2
]}

Itoh, Yoshinori ^{[1
]}

机构：

[1] Gifu Univ Hosp, Dept Pharm, Gifu 5011194, Japan

[2] Gifu Univ, Sch Med, Dept Urol, Gifu 500, Japan

来源：

ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2011年 / 61卷 / 03期

关键词：

Area under the concentration-time curve; CAS; 104987-11-3; Pharmacokinetics; Renal transplantation; Tacrolimus; once-daily formulation; Trough concentration; SOLID-ORGAN TRANSPLANTATION; KIDNEY-TRANSPLANTATION; CLINICAL-EXPERIENCE; RECIPIENTS; REJECTION; EXPOSURE; JAPANESE; THERAPY; REGIMEN;

D O I：

暂无

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The present study was designed to determine the pharmacokinetic profiles of a once-daily formulation of tacrolimus (CAS 104987-11-3; TAC-once) in patients before and after introduction of renal transplantation. Pharmacokinetic parameters for tacrolimus were almost comparable among patients receiving TAC-once before, 2 weeks after and 3 weeks after renal transplantation. Among various parameters, correlated most closely with the area under the concentration-time curve during 24 h (AUC(0-24)) (R-2 = 0.82, P < 0.001), while no consistent correlation was observed between AUC0-24 and concentrations at 2 h or 4 h, or the dose of TAC-once. The clinical outcomes such as the incidence of acute rejection, renal tissue injury and cytomegalovirus infection were evaluated during the first 3 weeks and 3 months after transplantation, and the data were compared with the historical data obtained from patients who had received the conventional twice-daily formulation of tacrolimus (TAG-twice). There were no significant differences in the incidence of such clinical outcomes between the two groups. These findings suggest that C-trough is useful for therapeutic monitoring of tacrolimus in patients receiving TAC-once. In addition, pharmacokinetics and clinical outcomes were comparable between TAC-once and TAC-twice formulations.

引用

页码：191 / 196

页数：6

共 18 条

[1] Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients [J].